Navigation Links
Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
Date:12/10/2008

from artificial insemination, a market that is currently valued at over $2.5 billion.

The Company submitted new provisional patents for inventions relating to SST which describe new discoveries that would significantly strengthen its proprietary process for separating X and Y chromosome-containing sperm.

The Company is working to identify all sex specific proteins and characterize them. Microbix took the necessary steps to ensure that it has built a solid patent foundation in 2008.

Urokinase

The Company's $2.5 million acquisition of all Urokinase assets from ImaRx Therapeutics, Inc. of Tucson, Arizona, (Nasdaq: IMRX) resulted in a major transformation for Microbix.

These assets included ImaRx' remaining Urokinase inventory (worth approximately US$40 million in retail value) as well as the regulatory file for the product (formerly known as Abbokinase(R), now rebranded as Kinlytic(R)), key raw materials for Urokinase manufacture, and the corresponding sales and marketing infrastructure).

With this acquisition, Microbix will become a fully integrated biopharmaceutical company with an established revenue base. The acquired inventory has a pending US FDA product inventory release which it expects in the coming weeks, allowing it to begin sales and marketing activities in the second quarter fiscal 2009.

By carefully parceling out the inventory, Microbix expects to have sufficient time to garner approval of its new product manufactured at its Skyway Urokinase manufacturing facility. Profits from Urokinase sales will be used to fund development of the Skyway operation.

Other Highlights

Microbix raised $6.825 million in equity through a brokered private placement financing. This placement had significant institutional investor participation. The fun
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
3. DuPont Leaders Brief Investors on Agriculture Businesses
4. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
5. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
8. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
9. Boydens Summit Practice Featured in the September Issue of New Jersey Business Magazine
10. Premier Research Appoints Melissa Jones as Vice President, International Business Development
11. Access Highlighted in Recent BusinessWeek Article
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... diagnostics company that develops and commercializes proprietary technologies ... announced that it has received approval from the ... 5,126,044 outstanding common share purchase warrants ("the Warrants") ... with the Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/16/2015)... South Carolina (PRWEB) April 17, 2015 ... and steam system services, released their newly designed, ... The customer facing website effectively promotes the ... , All the information that a site ... steam system services, company capabilities, industries serviced, the ...
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... by Stent Manufacturers Expected to ... - Witness Live Case Examples of Advanced Practices by Leading, Interventionalists, Broadcast from ... the Role of IVUS in Improving Stent, Results. - See How Many of the ... ...
... 22 Agendia BV, a,world leader in the rapidly ... Chief Research Officer Laura van ,t Veer has,received a ... Ribbon Breast Cancer Research Foundation. The Pink Ribbon ... 151 international breast cancer researchers with a total value ...
... CAMBRIDGE, Mass., Oct. 22 Genzyme Corp.,(Nasdaq: ... and Drug Administration,has granted marketing approval for Renvela(TM) ... patients with chronic kidney disease on,dialysis. Renvela is ... phosphate binder in the United States. "Since ...
Cached Biology Technology:Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 4FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 5
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... at Loyola University Chicago Stritch School of Medicine have ... Institutes of Health to study vitamin D deficiency in ... relation between low vitamin D levels and risks for ... Evidence from numerous previous studies is "inconclusive and needs ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has ... might lead to improvements in that and other crops. ... landscape architecture, wanted to understand the relationship between natural ... plant architecture, specifically plant height. Schulz said corn could ...
... at the University of North Carolina at Chapel Hill have ... different viruses in an effort to create the ultimate vehicle ... investigators found no side effects from using a "chimeric" virus ... patients with muscular dystrophy. "This trial demonstrates that gene ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Stronger corn? Take it off steroids, make it all female 2Stronger corn? Take it off steroids, make it all female 3Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2